electroCore Expands IP Portfolio for nVNS Technology

The U.S. Patent and Trademark Office has issued electroCore Inc. a patent related to a non-Vegas Nerve Stimulation (nVNS) treatment protocol.
 
U.S. Patent No. 11,779,756 titled, “Systems and Methods for Vagal Nerve Stimulation,” is generally related to a preferable nVNS treatment paradigm that involves applying a single dose of stimulation for about 90 seconds to about 150 seconds, two to four times during a 24-hour period.
 
“Our intellectual property portfolio continues to grow,” electroCore CEO Dan Goldberger said. “This new patent strengthens our position around the application of non-invasive vagus nerve stimulation, and how frequently nVNS may be used by a patient or customer looking for relief.”
 
electroCore Inc. is a commercial stage bioelectronic medicine and wellness company developing non-invasive vagus nerve stimulation technology. Its focus is the commercialization of medical devices for managing and treating certain medical conditions and consumer product offerings using nVNS to promote general well-being and human performance in the United States and select overseas markets.